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Mutations in NEXN, a Z-Disc Gene,
Are Associated with Hypertrophic Cardiomyopathy
Hu Wang,1,2,4 Zhaohui Li,1,4 Jizheng Wang,2 Kai Sun,2 Qiqiong Cui,3 Lei Song,2 Yubao Zou,2
Xiaojian Wang,2 Xuan Liu,2 Rutai Hui,2,* and Yuxin Fan1,*
Hypertrophic cardiomyopathy (HCM), themost common inherited cardiac disorder, is characterized by increased ventricular wall thick-
ness that cannot be explained by underlying conditions, cadiomyocyte hypertrophy and disarray, and increased myocardial fibrosis.
In as many as 50% of HCM cases, the genetic cause remains unknown, suggesting that more genes may be involved. Nexilin, encoded
byNEXN, is a cardiac Z-disc protein recently identified as a crucial protein that functions to protect cardiac Z-discs from forces generated
within the sarcomere. We screened NEXN in 121 unrelated HCM patients who did not carry any mutation in eight genes commonly
mutated in myofilament disease. Two missense mutations, c.391C>G (p.Q131E) and c.835C>T (p.R279C), were identified in exons
5 and 8 of NEXN, respectively, in two probands. Each of the two mutations segregated with the HCM phenotype in the family and
was absent in 384 control chromosomes. In silico analysis revealed that both of the mutations affect highly conserved amino acid resi-
dues, which are predicted to be functionally deleterious. Cellular transfection studies showed that the two mutations resulted in local
accumulations of nexilin and that the expressed fragment of actin-binding domain containing p.Q131E completely lost the ability to
bind F-actin in C2C12 cells. Coimmunoprecipitation assay indicated that the p.Q131E mutation decreased the binding of full-length
NEXN to a-actin and abolished the interaction between the fragment of actin-binding domain and a-actin. Therefore, the mutations
in NEXN that we describe here may further expand the knowledge of Z-disc genes in the pathogenesis of HCM.Cardiomyopathy is a primary heart-muscle disorder associ-
ated with cardiac dysfunction. On the basis of morpholog-
ical and functional characteristics, it is classified into
four categories: hypertrophic, dilated, arrhythmogenic
right ventricular, and restrictive.1 Hypertrophic cardiomy-
opathy (HCM [MIM 192600]) is characterized by hyper-
trophy and diastolic dysfunction of cardiac ventricles
accompanied by cardiomyocyte hypertrophy, fibrosis, and
myofibrillar disarray.2 Diagnostic criteria for HCM in
adults are defined by a maximal left ventricular wall thick-
ness of R 13 mm on echocardiography in the absence of
other loading conditions such as hypertension or aortic
valve stenosis. Occurring in approximately 1 in 500 indi-
viduals, HCM is the most common heritable cardiac
disorder and often follows an autosomal-dominant inher-
itance pattern with incomplete penetrance.3 HCM can
manifest negligible to extreme hypertrophy, minimal to
extensive fibrosis and myocyte disarray on microscopy,
absent to severe left-ventricular ouflow-tract obstruction,
and distinct septal morphologies. The clinical course also
varies considerably, from a benign asymptomatic course
to that of severe heart failure and sudden cardiac death
(SCD). HCM is the most common cause of SCD in young
and competitive athletes.3,4 In recent studies, the annual
rate of SCD from HCM varies between 0.1% and 1.7%,
a subset of patients having an estimated annual SCD prob-
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The AmericanHCM is usually caused by mutations in genes that
encode components of the cardiac muscle sarcomere.
To date, hundreds of mutations implicated in the patho-
genesis of HCM have been reported in nine genes encod-
ing sarcomeric filament proteins: b-myosin heavy chain
(MYH7 [MIM 160760]), cardiac myosin-binding protein
C (MYBPC3 [MIM 600958]), cardiac troponin T (TNNT2
[MIM 191045]), cardiac troponin I (TNNI3 [MIM 191044]),
cardiac troponin C (TNNC1 [MIM 191040]), cardiac a-actin
(ACTC1 [MIM 102540]), a-tropomyosin (TPM1 [MIM
191010]), essential myosin light chain (MYL3 [MIM
160790]), and regulatory myosin light chain (MYL2
[MIM 160781]). Among these genes, mutations in MYH7,
MYBPC3, TNNI3, and TNNT2 occur most often and
account for as many as 50% of reported genotyped HCM
cases.7–10
With a large portion of HCM cases being genetically
unexplained, genes encoding proteins involving potential
functional or transcriptional processes of the cardiomyo-
cyte, particularly those encoding the cytoarchitecture
proteins localized to the cardiac Z-disc, have been associ-
ated with disease pathogenesis. The Z-disc complex is
located at either end of the contractile unit of the striated
muscle and links titin and actin filaments from opposing
sarcomere halves in a lattice connected by a-actinin. The
Z-discs provide a backbone for the insertions of actin-based
thin filaments and represent a key interface between theylor College of Medicine, Houston, TX 77030, USA; 2Sino-German Labora-
inese Academy of Medical Sciences, Peking Union Medical College, Beijing
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contractile apparatus and the cytoskeleton. In addition,
the complex molecular network of Z-disc proteins is
pivotal for reception, transduction, and transmission of
mechanical and biochemical signals.11,12 During recent
years, the Z-disc has become the focus of research, and
new functions beyond a sole passive mechanical trans-
mitter of force have emerged.13 Particularly, as a potential
myocardial ‘‘stretch receptor,’’ the Z-disc would enable the
cardiomyocyte to sense increased mechanical load and
respond with changes in gene expression, ultimately re-
sulting in cellular hypertrophy.14,15 Because of the Z-disc’s
importance in establishing the mechanical coupling and
as the stretch-sensor mechanism of the sarcomere, genes
encoding these Z-disc proteins were hypothesized to be
excellent candidates for involvement in HCM.16 In 2003,
the first Z-disc mutations implicated in HCM were
described in muscle LIM protein encoded by CSRP3
(MIM 600824), which comprises two LIM domains, the
first of which directly binds to a-actinin.17 In 2004, two
missense mutations in telethonin, which is a Z-disc
protein encoded by TCAP (MIM 604488) and represents
an important link between titin and other Z-disc-associ-
ated proteins, were identified in a cohort of HCM cases.18
Recent studies have reported that mutations in another
five Z-disc genes, LDB3 (MIM 605906; encoding LIM
domain binding 3), ACTN2 (MIM 102573; encoding
a-actinin 2), VCL (MIM 193065; encoding vinculin),
MYOZ2 (MIM 605602; encoding myozenin 2), and
ANKRD1 (MIM 609599; encoding ankyrin repeat domain
1), are responsible for HCM.19–21
Recently, a cardiac Z-disc protein, nexilin, encoded by
NEXN (MIM 613121), has been identified as a crucial
protein that functions to protect cardiac Z-discs from
forces generated within the sarcomere that, whenmutated,
lead to dilated cardiomyopathy in both humans and zebra-
fish.22 Nexilin, consisting of 675 amino acids, was isolated
previously as an F-actin-binding protein at cell-matrix
adherens junctions.23 Hassel and colleagues found that
nexilin is highly abundant in the heart and skeletal muscle
and is located specifically to the Z-disc; loss of nexilin in
zebrafish led to perturbed Z-disc stability and heart
failure.22 Moreover, these researchers identified one dele-
tion and two missense mutations in NEXN in a large
cohort of patients with dilated cardiomyopathy (DCM
[MIM 115200]).22 These mutations account for approxi-
mately 1% of the patients studied.
On the basis of the understanding that nexilin plays
a unique role in stabilizing and protecting Z-discs from
mechanical trauma and that mutations of certain sarco-
meric and sarcomeric-associated genes identified in DCM
also are known to cause HCM, we hypothesized that muta-
tions in NEXN might be involved in the pathogenesis of
HCM. Therefore, we performed sequencing analysis of
NEXN in a cohort of 121 unrelated Han Chinese patients
with HCM who previously had not been found to carry
mutations in eight commonmyofilament-associated genes
(MYH7, MYBPC3, MYL2, MYL3, TNNT2, TNNI3, TPM1,688 The American Journal of Human Genetics 87, 687–693, NovembACTC1) responsible for HCM.7 We selected 192 control
subjects from among healthy individuals matched on
the basis of gender and ethnic origin. All patients with
systemic hypertension, valvular heart disease, and congen-
ital heart disease, including subaortic, valvular, and supra-
valvular aortic stenosis and coarctation of aorta, were
excluded at the beginning of the study. Informed consent
was obtained from all participating individuals. This study
was approved by the institutional review board of the
Cardiovascular Institute, Chinese Academy of Medical
Sciences.
Genomic DNA was isolated from peripheral blood
leukocytes with a standard salting-out protocol. Primer
pairs were designed to amplify all of the coding regions
and the intron-exon boundaries of NEXN based on the
published sequence (GenBank accession number NM_
144573.3). PCR amplifications were performed with the
use of standard protocols, and PCR products were ana-
lyzed by direct sequencing on an Applied Biosystems
3730 Genetic Analyzer with BigDye Terminator chemistry
(version 3.1).
We identified two heterozygous missense mutations,
c.391C>G (p.Q131E) and c.835C>T (p.R279C), which
are located in exons 5 and 8, respectively, in NEXN in
two probands with familial HCM (Figure 1). Both of the
mutations affect highly conserved amino acid residues
among 12 interspecies orthologs and are located in the
important functional domains of nexilin (Figure 2). In
family A, the NEXN mutation p.Q131E was detected in
individuals II:2, II:3, and III:1, and this mutation segre-
gated with the HCM phenotype in the family members.
The proband (II:2) was a 37-year-old female diagnosed
with HCM because of typical HCM clinical features. The
echocardiogram showed that she had a nonobstructive
cardiac hypertrophy with an interventricular septal
thickness of 21 mm with normal left ventricular systolic
function and an abnormal electrocardiogram (ECG) with
T-wave changes. The proband’s mother (I:2) had died of
SCD at the age of 38 years. Her 34-year-old brother (II:3)
and her 16-year-old daughter (III:1), each of whom carry
the p.Q131E mutation, also were found to be affected,
and the echocardiogram demonstrated that both of them
had asymmetrical septal hypertrophy. In addition, II:3
showed an abnormal ECG indicating voltage criteria for
left ventricular hypertrophy. The other family members,
her father (I:1) and her daughter (III:2), did not demon-
strate any clinical evidence of HCM on echocardiography
or ECG. Individuals II:4 and III:3 had not had clinical eval-
uation and genetic testing.
In family B, the proband (III:2), a 45-year-old male
carrying the NEXN mutation p.R279C, was diagnosed
with HCM, with a left ventricular anterior wall thickness
of 17 mm. His grandmother (I:2) had died suddenly with
suspected heart disease at 40 years of age. His father (II:1)
and his younger brother (III:4) were diagnosed subse-
quently with HCM as a result of clinical screening of the
family, and the mutation p.R279C was detected in bother 12, 2010
Figure 1. Mutation Analysis of NEXN in Familial Hypertrophic Cardiomyopathy
Filled symbols indicate clinically affected individuals; open symbols indicate unaffected individuals; half-filled symbol indicates sus-
pected affected individual; a slash through a circle or square indicates a deceased individual; plus (þ) and minus () signs indicate
the presence or absence of a mutation in NEXN, respectively; symbol with ‘‘?’’ indicates an individual who did not have clinical evalu-
ation and genetic testing; squares indicate males; circles indicate females; shaded symbol indicates an individual who was not included
in the LOD score calculations. The proband patient in each family is marked with an arrow. The right part of each panel indicates direct
sequencing data of NEXN mutant sequences compared with a normal control.
(A) Pedigree of Family A. NEXN mutation p.Q131E was identified in II-2, II-3, and III-1.
(B) Pedigree of Family B. NEXN mutation p.R279C was identified in II-1, III-2, III-4, and IV-1.of them. The echocardiogram showed that his father had
asymmetrical left ventricular hypertrophy with an anterior
wall thickness of 22 mm, and the ECG revealed atrial fibril-
lation and ST-T changes. His younger brother was found to
have moderate asymmetrical interventricular septal thick-
ness (16 mm), with an abnormal ECG indicating voltage
criteria for left ventricular hypertrophy. The proband’s
daughter (IV:1) also carried the same mutation and was
clinically asymptomatic; however, because she was only
12 years of age at the time of evaluation, she most likely
was in the presymptomatic phase of the disease. Clinical
findings of the individuals with and without NEXN muta-
tions in the two Chinese HCM families are summarized inThe AmericanTable 1 and Table S1 (available online), respectively.
Linkage analysis was performed in the two pedigrees
with the use of Linkage 5.1. Individual IV:1 in family B is
assumed to be below the age of onset and, hence, is not
included in the calculation. The LOD score is 0.60 for
family A and 0.56 for family B. The combined LOD score
of the two pedigrees is 1.16, suggesting that the observed
segregation would occur at a random chance of less than
1 in 14. Although the NEXN mutations segregate with
HCM in these families, the small sample size may limit
the strength of the linkage signal.
To exclude the possibility that the two identified
sequence variants (p.Q131E and p.R279C) are rareJournal of Human Genetics 87, 687–693, November 12, 2010 689
Figure 2. Location and Conservation of
the NEXN Protein Amino Acid Residues
Affected by the Mutations
NEXN is a 13-exon gene encoding two
N-terminally locatedactin-bindingdomains
(ABD), a coiled-coil domain (CC), and a
C-terminal immunoglobulin superfamily
class (IGcam).
(A) Schematic structure of NEXN mRNA
and protein. The p.Q131E mutation is
located in exon 5 and in the first actin-
binding domain; the p.R279C mutation is
located in exon 8 and in the coiled-coil
domain.
(B) NEXN peptide sequences surrounding
the mutated residues (black box) with
multiple interspecies alignments generated
by ClustalW. Q131 and R279 amino acid
residues of NEXN are highly conserved
across species.polymorphisms without functional significance, we first
confirmed that the two variants were not reported in the
NCBI dbSNP database. Furthermore, neither of the two
mutations could be identified in 192 ethnically matched
healthy control subjects. To further confirm that the two
mutations (p.Q131E and p.R279C) are likely to be disease
causing, we applied two commonly used in silico algo-
rithms, PolyPhen-2 and SIFT, to predict the putative effects
of the two mutations on protein function.24–26 Both of the
two algorithms strongly suggested that the two NEXN
sequence variants might be disease-causing mutations.
In addition to the two mutations, we also identified two
SNPs, c.733G/A (p.G245R [rs1166698]) and c.1419A/G
(p.R473R [ss252441070]), the frequency of each having
no significant difference between HCM cases and controls
(Table S2).
HCM has long been considered a disease of the sarco-
mere, more specifically a disease of the myofilamentTable 1. Clinical Features of Affected Patients with NEXN Mutations
Family and Subject Sex Age (Yrs) SBP/DBP LVmax PW L
Family A
II:2 F 37 128/76 21 11 2
II:3 M 34 122/82 18 10 2
III:1 F 16 108/70 14 8 2
Family B
II:1 M 67 135/85 22 12 3
III:2 M 45 132/80 17 9 2
III:4 M 43 129/75 16 10 3
IV:1 F 12 95/62 11 7 2
F, female; M, male; SBP/DBP, systolic blood pressure/diastolic blood pressure (mm
ness (mm); LVESD, left ventricular end–systolic diameter (mm); LVEDD, left vent
(mm); EF, ejection fraction; ECG, electrocardiogram; AF, atrial fibrillation.
690 The American Journal of Human Genetics 87, 687–693, Novembbecause of the hundreds of mutations scattered
throughout the genes that encode proteins of the myofila-
ment. With the recent discovery of HCM-associated muta-
tions in genes encoding proteins of the Z-disc17–21 and
proteins involved in calcium-induced calcium release,27,28
the body of knowledge regarding the genetic spectrum of
HCM continues to expand. Nexilin, encoded by NEXN
and recently isolated as a Z-disc protein, plays an impor-
tant role in stabilizing and protecting Z-discs from
mechanical forces.22 Nexilin is expressed specifically in
heart and skeletal muscle and contains two N-terminally
located actin-binding domains (ABD), a coiled-coil domain
(CC), and a C-terminal immunoglobulin superfamily class
domain (IGcam) (Figure 2). Hassel and colleagues identi-
fied one deletion mutation (p.G650 del) and two missense
mutations (p.P611Y and p.Y652C) in NEXN in a large
cohort of patients with dilated cardiomyopathy. Notably,
the three identified NEXN mutations reside in the ratherVESD LVEDD LA EF (%) ECG Mutation
8 46 37 67 T-wave changes p.Q131E
9 45 40 62 LVH voltage criteria p.Q131E
6 39 41 57 normal p.Q131E
9 57 46 55 AF, ST-T changes p.R279C
8 45 38 65 normal p.R279C
0 51 35 71 LVH voltage criteria p.R279C
5 38 34 59 normal p.R279C
Hg); LVmax, left ventricular wall maximal thickness; PW, posterior wall thick-
ricular end–diastolic diameter (mm); LA, left atrial anterior-posterior diameter
er 12, 2010
Figure 3. Distribution of V5-Tagged
NEXN in C2C12 Cells
C2C12 cells transfected with V5-tagged
full-length wild-type (WT) (A–C) or mu-
tants p.Q131E (D–F) and p.R279C (G–I) or
with V5-tagged first actin-binding domain
(ABD) (J–L) or mutant NEXNABD-p.Q131E
(M–O). NEXN constructs were fixed 24 hr
after the transfection and stained by a V5
antibody followedby a secondary antibody
(A, D, G, J, M) and incubated with phalloi-
din andDAPI (B, E,H, K,N) (Magnification:
4003). Merged images (C, F, I, L, O) are
shown. Overexpression of wild-type
NEXN was preferentially distributed along
F-actin, whereas mutants p.Q131E and
p.R279C showed partially abnormal aggre-
gates in the cytoplasm. Expression of the
NEXNABD fragment of amino acids 1–164
in C2C12 cells showed that this fragment
tended to be localized in the nucleus and
was partially distributed along F-actin,
whereas the mutant NEXNABD-p.Q131E
fragment was completely dispersed into
the nucleus and cytoplasm.restricted region of amino acids 611–652 located in the
IGcam domain of nexilin. Interestingly, the two muta-
tions, p.Q131E and p.R279C, that we identified in the
Chinese patients with HCM are located in the first ABD
and CC, respectively, each of which is closer to the
N terminus of nexilin.
The differences in the location of mutations identified
in the two cohort studies may implicate that the molecular
mechanisms underlying the NEXN-related pathogenesis
for DCM and HCM might be different. To determine
whether the NEXN mutations, p.Q131E and p.R279C,
affect the localization of nexilin protein and its binding
ability to a-actin, we created NEXN expression vectors
and performed an immunocytochemistry study. Because
the p.Q131E mutation is exactly situated in the first
actin-binding domain of nexilin, we also generated frag-
ment clones containing this binding domain to better
understand the effects of the mutation on actin binding.
The human full-length NEXN cDNA and the fragment
encoding the first ABD (amino acids 1–164) were cloned
into pcDNA3.1/V5 vector. Mutants were generated by site-
directed mutagenesis, and all generated constructs wereThe American Journal of Human Genetconfirmed by direct sequencing. Cul-
tured C2C12 cells were transfected
with the wild-type or mutant V5-
tagged NEXN constructs with the use
of Lipofectamine 2000. Cells were
stained by rabbit V5 polyclonal anti-
body followed by secondary donkey
FITC-conjugated antibody to rabbit
IgG, and Alexa Fluor 633 conjugated
to phalloidin was used for F-actin
staining. Nuclei were stained with40,6-diamidino-2-phenylindole dihydrochloride (DAPI).
The results showed that the wild-type NEXN was preferen-
tially distributed along F-actin, whereas the mutants
p.Q131E and p.R279C presented local accumulations in
the cytoplasm (Figure 3). Expression of the NEXNABD frag-
ment (amino acids 1–164) in C2C12 cells showed that
this fragment tended to aggregate in the nucleus and
was partially distributed along F-actin; however, when
p.Q131E was introduced, the mutant NEXNABD fragment
was entirely dispersed into nucleus and cytoplasm and
completely lost the ability to bind to F-actin (Figure 3).
Similar results were observed in differentiated C2C12 cells
(Figure S1). Noticeably, intranuclear accumulation of the
NEXNABD fragment points to the possibility that a cyto-
plasmic localization signal (CLS) exists at the C-terminal
part of nexilin. Immunoblot analysis did not show obvious
differences in the protein levels of full-lengthwild-type and
mutants or between NEXNABD and NEXNABD-p.Q131E
(Figure S2). To verify the above findings in immunocyto-
chemistry, we then performed a coimmunoprecipitation
study. The human a-actin cDNA was cloned into
pcDNA3.1/NT-GFP vector and was cotransfected withics 87, 687–693, November 12, 2010 691
Figure 4. Binding of NEXN to a-Actin
Binding of the full-length NEXN and NEXN fragment to a-actin
was analyzed by coimmunoprecipitation and subsequent immu-
noblotting. Lysates fromHEK293 cells cotransfected with NT-GFP-
tagged a-actin and V5-tagged NEXN constructs (NEXN, NEXN-
p.Q131E, NEXN-p.R279C, NEXNABD, or NEXNABD-p.Q131E) were
immunoprecipitated with a V5-specific antibody (IP: V5) and
subsequently immunoblotted with a HRP-conjugated V5- and
GFP-specific antibody. Untransfected cells served as negative con-
trols. Inputs were cell lysates subject to immunoblotting without
immunoprecipitation.NEXN-V5 vectors intohuman embryonic kidney (HEK) 293
cells. Immunoprecipitation and subsequent immunoblot-
ting were performed, with slight variations, as previously
described.29Our results showed that the p.Q131Emutation
decreased the binding of full-length NEXN to a-actin and
abolished the binding of the NEXNABD-p.Q131E mutant
fragment to a-actin (Figure 4). In addition, the p.R279C
mutation did not change the binding ability of nexilin to
a-actin. However, we cannot exclude the possibility that
this mutation might be involved in the binding of nexilin
to other components of the sarcomere or Z-disc. Taken
together, our findings provide the biochemical basis for
the possible pathogenesis of HCM associated with NEXN
mutations.
The Z-disc has received extensive attention recently in
cardiac hypertrophy research because mutations in genes
encoding several of its constituents have been shown to
cause hypertrophic cardiomyopathy.7,13,16,19,20 Proteins
of Z-discs are important in stabilizing sarcomere, inte-
grating mechanical forces, and distributing these within
the muscle cell and to the extracellular matrix. In addition,
they appear to serve as a docking station for transcription
factors, Ca2þ signaling proteins, kinases, and phosphatases
and as a way station for proteins that regulate transcription
by aiding in their controlled translocation between the
nucleus and the Z-disc.13,30 With these roles, a main impli-
cation for the Z-disc is its involvement in the cardiomyo-
cyte stretch-sensing and -response systems, which may
transduce multiple signaling pathways during stress, trans-
lating into hypertrophic responses and remodeling.15,31
Nexilin has a unique role in stabilizing cardiac Z-discs
and is essential for maintaining Z-disc integrity against692 The American Journal of Human Genetics 87, 687–693, Novembthe extreme forces generated during muscle contraction.22
As a recently identified member of the Z-disc gene family
and because of the potential differences between HCM
and DCM in the pathogenesis caused by NEXN defects,
the function of NEXN remains to be further elucidated.Supplemental Data
Supplemental Data include two tables and two figures and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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